Single center, open labeled, phase 2 clinical trial, where patients with metastatic
colorectal cancer are selected for treatment with dose dense Cyclophosphamide every second
week based on TP53 mutation status; i.e. only patients with TP53 mutated tumors may be
included in the treatment arm.